Magnesium Aluminum Silicate

Thaned Pongjanyakul, et al. Journal of controlled release, 2005, 107(2), 343-356.

A film composed of sodium alginate-magnesium aluminum silicate (SA-MAS) was created and tested for use as a film former for dispersions to control drug release from tablets, thanks to the interaction between MAS and SA to form a phase-separated microcomposite.
· Preparation of SA and SA-MAS films
SA and SA-MAS composite films were prepared using a casting/solvent evaporation method. SA (2 g) was dispersed in distilled water with a homogeniser for 5 minutes, diluted to a final volume of 200 ml, and kept overnight at room temperature. The dispersion was cast on to a plastic sheet (15 cm x 20 cm) and dried at 50°C. The films were peeled and put in a desiccator. To incorporate MAS into the films, pre-hydrated MAS (1 g, 2 g, or 3 g) was mixed with the SA dispersion using a homogenizer for 5 minutes, followed by the casting and drying process.
· Preparation of SA-MAS coated tablets
The tablet formulation consisted of 10% active ingredient (propranolol HCl (PPN) or acetaminophen (ACT)), 30% microcrystalline cellulose, 58.8% spray-dried lactose, 0.2% colloidal silicon dioxide, and 1% magnesium stearate. The tablets were coated with a 3% w/v low-viscosity SA (LV-SA) dispersion or a 2% w/v LV-SA and 2% w/v MAS dispersion. Coating conditions were as follows: tablet weight 900 mg, inlet air temperature 60-65°C, spray rate 4 ml/min, and spray pressure 0.28 MPa.

Ezeibe, Maduike,, et al. British Journal of Medicine and Medical Research, 2015, 9(6), 1-8.

This study suggested that lower doses of aluminum magnesium silicate (AMS)-stabilized antimicrobials combined with immunostimulants may be used to prevent and treat drug-resistant infections.
· Mechanism of Action
Stabilization of ampicillin trihydrate, sulfadimethoxine, piperazine citrate, and chloroquine phosphate with pharmaceutical synthetic aluminum magnesium silicate and supportive treatment with immunostimulants can prolong their bioavailability, enhance the patient's immune response, and improve treatment efficacy, thereby clearing 95% or more of sensitive and resistant infections.
· Efficacy evaluation of AMS-stabilized antimicrobials
The recommended dosages of Piparazine, Ampicillin, and Chloroquine achieved clearances of only 82.94%, 80.68%, and 20% for infections caused by Helignosomoides bakeri, Salmonella gallinarum, and Plasmodium berghei, respectively. Administering lower doses (75%) of AMS-stabilized Piparazine and Ampicillin resulted in clearances of 96.82% and 97.84% for the respective infections. When the AMS-stabilized Chloroquine and AMS-stabilized Ampicillin were combined with immune stimulants, complete clearance of P. berghei infections was achieved, along with a clearance rate of 95.80% for Ampicillin-resistant Escherichia coli infections.